<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343417">
  <stage>Registered</stage>
  <submitdate>30/08/2011</submitdate>
  <approvaldate>31/08/2011</approvaldate>
  <actrnumber>ACTRN12611000935932</actrnumber>
  <trial_identification>
    <studytitle>Clinical pharmacokinetics of metformin in Australian Aboriginal and Torres Strait Islanders</studytitle>
    <scientifictitle>A study of factors affecting the concentrations of metformin in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes</scientifictitle>
    <utrn>U1111-1123-9802</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Australian Aboriginal patients who are taking metformin for their type 2 diabetes are required to provide a minimum of 1 blood sample and a maximum of 6 blood samples on different occasions. There are no fixed timing period. Blood samples are used to determine metformin concentrations, glycosylated haemoglobin (HbA1c), creatinine, vitamin B12 and lactic acid concentration. The overall duration of this study is 24 months.</interventions>
    <comparator>Not applicable.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate whether the pharmacokinetics of metformin is different in Australian Aboriginal and Torres Strait Islander patients compared to non-Indigenous Australians.</outcome>
      <timepoint>Data analysis at the end of recruitment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate factors influencing the pharmacokinetics of metformin between Australian Aboriginal patients. This includes the influence of kidney function (creatinine clearance), body size descriptors (weight) and age. These factors will be used as covariates in a population pharmacokinetic model to investigate inter-patient variability in metformin pharmacokinetics.</outcome>
      <timepoint>At the first instance for each patient.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Australian Aboriginal or Torres Strait Islander patients with type 2 diabetes and taking metformin.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients unable to provide informed consent to participate in the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2036</postcode>
    <postcode>4870</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Richard Day</primarysponsorname>
    <primarysponsoraddress>Dept of Clinical Pharmacology and Toxicology
Level 2, St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>ARC Linkage Grant</fundingname>
      <fundingaddress>Level 2, 11 Lancaster Place
Majura Park ACT 2609
AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the use of metformin in Australian Aboriginal and Torres Strait Islander patients with type 2 diabetes. The aim of this study is to compare the pharmacokinetics of metformin in Australian Aboriginal and non-Aboriginal Australians patients. It involves obtaining a medical history of the patient and asking patients about their metformin formulation, dose, dosing times and their compliance to the medication.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Aboriginal Health and Medical Research Council (AH&amp;MRC) Ethics Committee</ethicname>
      <ethicaddress>Level 3, 66 Wentworth Ave
Surry Hills NSW 2010</ethicaddress>
      <ethicapprovaldate>27/05/2011</ethicapprovaldate>
      <hrec>1/11/0785</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Base Hospital HREC</ethicname>
      <ethicaddress>Cairns Base Hospital
PO Box 902
Cairns QLD 4870</ethicaddress>
      <ethicapprovaldate>9/05/2011</ethicapprovaldate>
      <hrec>HREC/11/QCH/33-727</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Richard Day</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 8382 2304</phone>
      <fax />
      <email>r.day@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janna Duong</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone>+61 2 8382 2309</phone>
      <fax />
      <email>janna.duong@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janna Duong</name>
      <address>Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>